Nicola Redfern
Cell and gene therapies represent one of the most promising frontiers in modern medicine, with the potential to significantly improve quality of life and even cure certain conditions. However, progress is still being slowed by challenges related to regulation, reimbursement, resource constraints, and limited awareness among both clinicians and patients.
As the field advances through 2026 and beyond, therapies are expected to expand into a broader range of conditions and become more integrated into routine clinical practice. Improving manufacturing, logistics, and delivery will be essential to making these treatments more accessible. At the same time, the industry must focus on earlier collaboration across stakeholders, better patient engagement, and clearer public information to support informed decision-making. Addressing these factors will be key to translating scientific innovation into real-world impact.
